88IV - PR Newswire Asia's news


Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ... 2024-06-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO BEIJING and SHANGHAI and CHICAGO , June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C ... 2024-06-02T Banking/Financial Service Health Care/Hospital Medical/Pharmaceuticals
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in ... 2024-06-02T Health Care/Hospital Medical/Pharmaceuticals
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting SAN FRANCISCO , U.S. and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ... 2024-06-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting SAN FRANCISCO , U.S. and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ... 2024-06-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting SHANGHAI and CHICAGO , June 2, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the ... 2024-06-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting CHICAGO , June 2, 2024 /PRNewswire/ -- On June 1 st , 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for ... 2024-06-02T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling! ONTARIO, Calif. , June 1, 2024 /PRNewswire/ -- Mark your calendars, grill masters! Z Grills, the innovator in premium wood pellet grills, is sizzling up summer with a groundbreaking promotion that's ... 2024-06-01T Food/Beverages Household/Consumer/Cosmetics Retail
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple BEIJING , May 30, 2024 /PRNewswire/ -- This is a report from China.org.cn about the Shaolin Temple: ... 2024-06-01T
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse BOSTON , June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca ® mouse. The IGH-VDJ genes in ... 2024-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals